A patient advocacy group is suing the Trump administration for failing to disclose details of a recent settlement with Gilead Sciences over the patent rights to a pair of HIV prevention pills. The deal, which was reached last January, capped several years of litigation that began when the Centers for Disease Control and Prevention argued…
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which…
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, so far, rather modest. We plan to catch up on our reading, promenade with the official mascots, and putter about the castle….
President Trump escalated his demands that pharma companies lower U.S. drug prices in line with what other countries pay, sending letters to 17 major drug companies Thursday that called on them to take actions by Sept. 29. He specifically asked the firms to: provide their full portfolio of drugs to Medicaid patients at prices in…
The Trump administration is proposing a voluntary program in which pharmaceutical companies can offer rebates for a small number of therapies to hospitals that participate in a federal drug discount program, an effort to sort out a controversy that has roiled the health care industry. At issue is the 340B discount program, which was created…
Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where we have bright sunshine and much less humidity than in recent days. Who could ask for anything more? Actually, we could — it is time to reheat the coffee kettle…
Vinay Prasad had a problem. Several, actually. His staff at the Food and Drug Administration kept leaking to the press. He was under attack by President Trump’s allies after moving to pull a gene therapy off the market. Democrats were not happy with his Covid vaccine restrictions, and anti-vaccine advocates were lambasting him for approving…
George Tidmarsh, the Food and Drug Administration’s top drug regulator, will take on additional responsibilities on a temporary basis after the sudden departure of top official Vinay Prasad on Tuesday. Tidmarsh has been named acting director of the FDA’s Center for Biologics Evaluation and Research, FDA Commissioner Marty Makary said in an email viewed by…
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup…
WASHINGTON — Health secretary Robert F. Kennedy Jr. could “imminently” overhaul a key federal advisory panel that recommends which preventive services insurers must pay for, according to a person familiar with the plans. The person said that federal health officials are actively vetting new members for the U.S. Preventive Services Task Force. David Mansdoerfer, an…